| Title | Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | Tsui DChun Cheon, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R |
| Journal | Clin Lung Cancer |
| Volume | 23 |
| Issue | 2 |
| Pagination | e99-e103 |
| Date Published | 2022 03 |
| ISSN | 1938-0690 |
| Keywords | Anaplastic Lymphoma Kinase, Carbazoles, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Follow-Up Studies, Humans, Lung Neoplasms, Maximum Tolerated Dose, Piperidines, Protein Kinase Inhibitors, Survival Analysis, Trastuzumab |
| DOI | 10.1016/j.cllc.2021.06.012 |
| Alternate Journal | Clin Lung Cancer |
| PubMed ID | 34330640 |
| Grant List | P30 CA046934 / CA / NCI NIH HHS / United States |
Related Faculty:
Liming Bao, M.D., Ph.D.